Optimisation of DMPK by the inhaled route: Challenges and approaches

Current Drug Metabolism

Volumn 13, Issue 4, 2012, Pages 457-473

  Cooper, Anne E ^a   Ferguson, Douglas ^a   Grime, Ken ^b  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Affinity; Exposure; Inhalation; Lung pharmacokinetics; Solubility; Unbound fraction

Indexed keywords

BUDESONIDE; CROMOGLYCATE DISODIUM; FLUNISOLIDE; FORMOTEROL; ROFLUPONIDE; SALBUTAMOL; SALMETEROL; TERBUTALINE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ALKALINITY; ARTICLE; DOG; DRUG DISPOSITION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG RETENTION; DRUG SOLUBILITY; DRUG SOLUTION; HUMAN; LUNG; NEBULIZATION; NONHUMAN; PHARMACODYNAMICS; PROCESS OPTIMIZATION; RAT;

ADMINISTRATION, INHALATION; ANIMALS; HUMANS; LUNG; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84860635092     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012800166571     Document Type: Article

References (63)

1. Davies, D. Pharmacokinetics of inhaled substances. Postgrad. Med. J., 1975, 51(7), 69-75.
2. Gonda, I. The ascent of pulmonary drug delivery. J. Pharm. Sci., 2000, 89, 940-945.
3. Patton, J.; Fishburn, S.; Weers, J. The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc., 2004, 1, 338-344.
4. Labris, N.; Dolovich, M. Pulmonary drug delivery. Part 1: Physiological factors affecting therapeutic effectiveness of aerosolised medications. Br. J. Clin. Pharmacol., 2003, 56, 588-599. (Pubitemid 37491710)
5. Labris, N.; Dolovich M. Pulmonary drug delivery, Part II: The role of the inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolised medications. Br. J. Clin. Pharmacol., 2003, 56, 600-612. (Pubitemid 37491711)
6. Caramori, G.; Adcock, I. Pharmacology of airway inflammation in asthma and COPD. Pulm. Pharmacol. Ther., 2003, 16, 247-277. (Pubitemid 36870860)
7. Fernandes, C.; Vanbever, R. Preclinical models of pulmonary drug delivery. Expert Opin. Drug Deliv., 2009, 6, 1231-1245.
8. Gonda, I.; Schuster, J. Pulmonary delivery of drugs by inhalation. Drugs Pharmaceut. Sci., 2003, 126, 807-815.
9. Martonen, T.; Zhang, Z.; Yang, Y. Interspecies modelling of inhaled particle deposition patterns. J. Aerosol Sci. 1992, 23, 389- 406.
10. Lipworth, B. Pharmacokinetics of inhaled drugs. Br. J.Clin. Pharmacol., 1996, 42, 697-705. (Pubitemid 26417610)
11. Jenne, J.; Ahrens, R. Pharmacokinetics of beta-adrenergic compounds. Lung Biol. Health Dis., 1987, 31, 213-258.
12. Winkler, J.; Hochhaus, G.; Derendorf, H. How the lung handles drugs. Pharmacokinetic and pharmacodynamics of inhaled corticosteroids. Proc. Am. Thorac. Soc., 2004, 1, 356-363.
13. Forbes, B.; Bahman, A.; Dailey, L.; Ferguson, D.; Gerde, P.; Gumbleton, M.; Gustavsson, L.; Hardy, C.; Hassall, D.; Jones, R.; Lock, R.; Maas, J.; McGovern, T.; Pitcairn, G.; Somers, G.; Wolff, R. Challenges in inhaled product development and opportunities for open innovation. Adv. Drug Deliv. Rev., 2011, 63(1-2), 69-87.
14. Wenlock, M.; Austin, R.; Barton, P.; Davis, A.; Leeson, P. A comparison of physicochemical property profiles of development and marketed oral drugs. J. Med. Chem., 2003, 46, 1250-1256. (Pubitemid 36428230)
15. Tronde, A.; Norden, B.; Marchner, H.; Wendel, A.; Lennernäs, H.; Bengtsson, U. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. J. Pharm.Sci., 2003, 92, 1216-33. (Pubitemid 36676468)
16. Leeson, P.; St.Gallay, S.; Wenlock, M. Impact of ion class and time on oral drug molecular properties. Med. Chem. Commun., 2011, 2, 91-105.
17. Lizio, R.; Degenhard, M.; Nolte, T.; Lehr, C.; Sarlikiotis, A.W.; Borchard, G.; Jahn, W.; Klenner, T. Development of a new aerosol delivery system for systemic pulmonary delivery in anaesthetized and orotracheal intubated rats. Lab. Animals, 2001, 35, 261-270. (Pubitemid 32592316)
18. Dahlbäck, M.; Eirefelt, S.; Nerbrink, O. Aerosol delivery to the respiratory tract in experimental animals. In: Aerosol inhalation: recent research frontier; Marijnissen, J.; Gradon, L. Ed.; Kluwer Academic Publishers: Netherlands, 1996; pp. 235-246.
19. Hickey, A.; Mansour, H. Delivery of drugs by the pulmonary route. Drugs Pharmaceut. Sci., 2009, 189, 191-219.
20. Davies, N.; Feddah, M. A novel method for assessing dissolution of aerosol inhaler products. Int. J. Pharmaceut., 2003, 255, 175-187. (Pubitemid 36369601)
21. Rohataki, S.; Rhodes, G.; Chaikin, P. Absolute oral versus inhaled bioavailability : significance for inhaled drugs with special reference to inhaled glucocorticoids. J. Clin. Pharmacol., 1999, 39, 661- 663.
22. Tayab Z.; Hochhaus, G. Pharmacokinetic/pharmacdynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems. Expert Opin. Drug Deliv,. 2005, 2, 519-532. (Pubitemid 41683225)
23. Osier, M.; Oberdörster, G. Intracheal inhalation vs intratracheal instillation: differences in particle effects. Fundam. Appl. Toxicol., 1997, 40, 220-227.
24. Driscoll, K.; Costa, D.; Hatch, G.; Henderson, R.; Oberdorster G.; Salem H.; Schlesinger, G. Intratracheal instillation as an exposure technique for the evaluation of respiratory tract toxicity: uses and limitations. Toxicol. Sci., 2000, 55, 24-35. (Pubitemid 30252432)
25. Raab, O.; Yeh, H.; Newton, G.; Phalen, R.; Valasques, D. Deposition of inhaled monodisperse aerosol in small rodents. In: Inhaled Particles IV; Walton W., Ed.; Unwin: England, 1975; pp. 3-21.
26. Raab, O.; Al-Bayati, M.; Teaque S.; Rasolt, A. Regional deposition of inhaled monodisperse coarse and fine particles in small laboratory animals. Ann. Occup. Hyg., 1988, 1, 53-63.
27. Ballard, P.; Leahy, D.E.; Rowland, M. Prediction of in vivo tissue distribution from in vitro data. 1. Experiments with markers of aqueous spaces. Pharm. Res., 2000, 17, 660-663.
28. Rodgers, T.; Leahy, D.; Rowland, M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate- to-strong bases. J. Pharm. Sci., 2005, 94(6), 1259-76. (Pubitemid 40904190)
29. Rodgers, T.; Rowland, M. Physiologically-based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci., 2007, 96(11), 3153- 3154. (Pubitemid 350221211)
30. Kurz, H.; Fichtl, B. Binding of drugs to tissues. Drug Metab. Rev., 1983, 14(3), 467-510. (Pubitemid 13077089)
31. Brown, R.; Schanker, L. Absorption of aerosolized drugs from the rat lung. Drug Metab. Disp.,1983, 11{4) 355-60. (Pubitemid 13035486)
32. Nakanishi, T.; Haruta, T.; Shirasaka, Y.; Tamai, I. Organic cation transporter-mediated renal secretion of ipratropium and tiotropium in rats and humans. Drug Metab. Disp., 2011, 39, 117-122.
33. Koepsell, H. Polyspecific organic cation transporters: their functions and interactions with drugs. Trends Pharmacol. Sci., 2004, 25(7), 375-381. (Pubitemid 38829491)
34. Sakagami, M.; Byron, P.; Respirable Microspheres for inhalation. Clin. Pharmacokinet., 2005, 44, 263-277.
35. Ishimura, M.; Yaguti, H.; Yoshitsugu, H.; Naito, S.; Satoh,T. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. J. Pharm Soc. Japan, 2003, 123(5), 369-375. (Pubitemid 41327466)
36. Forkert, P.; Baldwin, M.; Millen, B.; Lash, L.; Putt, D.; Shultz, M.; Collins, K. Pulmonary bioactivation of trichloroethylene to chloral hydrate: relative contributions of CYP2E1, CYP2F and CYP2B1. Drug Metab. Disp., 2005, 33, 1429-1437. (Pubitemid 41323989)
37. Lee, C.; Watt, K.; Chang, A.; Plopper, C.; Buckpitt, A.; Pinkerton, K. Site-selective differences in cytochrome P450 isoform activities : comparison of expression in rat and rhesus monkey lung and induction in rats. Drug Metab. Disp., 1998, 26(5), 396-400. (Pubitemid 28223879)
38. Anttila, S.; Tuominen, P.; Hirvonen, A.; Nurminen, M.; Karjalainen, A.; Hankinson, O.; Elovaara, E. CYP1A1 levels in lung tissue of tobacco smokers and polymorphisms of CYP1A1 and aromatic hydrocarbon receptor. Pharmacogenetics, 2001, 11, 501- 509. (Pubitemid 32780554)
39. Anttila, S.; Hakkola, J.; Tuominen, P.; Elovaara, E.; Husgafvel-Pursiainen, K.; Karjalainen, A.; Hirvonen, A.; Nurminen, T. Methylation of cytochrome P4501A1 promoter in the lung is associated with tobacco smoking. Cancer Res., 2003, 63, 8623 -8628. (Pubitemid 38064036)
40. Kim, J. Sherman, M.; Curriero, F.; Guengerich, F.; Strickland, P.; Sutter, T. Expression of cytochrome P450 1A1 and 1B1 in human lung from smoker, non-smokers and ex-smokers. Toxicol. Appl. Pharmacol., 2004, 199, 210-219. (Pubitemid 39208722)
41. Hecht S. Tobacco Smoke Carcinogens and lung cancer. J. Natl. Cancer Inst., 1999, 91: 1194-1210. (Pubitemid 29357186)
42. Uetrecht, J. Prediction of a new drug's potential to cause idiosyncratic reactions. Curr. Opin. Drug Discov. Devel., 2001, 4(1), 55- 59. (Pubitemid 32118459)
43. Tronde, A.; Bosquillon, C.; Forbes, B. The isolated perfused lung for drug absorption studies. Biotechnology: Pharmaceutical Aspects, 2008, 7, 135-163.
44. Kedem, E.; Shahar, E.; Hassoun, G.; Pollack, S. Iatrogenic Cushing's Syndrome due to Coadministration of Ritonavir and Inhaled Budesonide in an Asthmatic Human Immunodeficiency Virus Infected Patient. J. Asthma, 2010, 47(7), 830-831.
45. Cazzola, M.; Testi, R.; Matera, M. Clinical pharmacokinetics of salmeterol. Clin. Pharmacokinet., 2002, 41(1), 19-30. (Pubitemid 34158086)
46. Minchin, R.; Johnston, R.; Akien, M.; Boyd, M. Pharmacokinetics of doxorubicin in isolated lungs of dogs and humans perfused in vivo. J. Pharmacol. Exp. Ther., 1984, 229, 193-198. (Pubitemid 14082931)
47. Taylor, K.; Taylor, G.; Kellaway, I.; Stevens, J. The Influence of Liposomal Encapsulation on Sodium Cromoglycate Pharmacokinetics in Man. Pharm. Res., 1989, 6, 633-636. (Pubitemid 19214431)
48. Omri, A.; Beaulac, C.; Bouhajib, M.; Montplasisir, S.; Sharkawi, M.; Lagace, J. Pulmonary retention of free and liposomeencapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 1994, 38, 1090-1095. (Pubitemid 24150843)
49. Marlow, M., Wollacott, J.; Fisk, J.; Berry, A.; Cooper, A. Liposomes: a tool for extended release of drugs in preclinical development. J. Pharm. Pharmacol., 2010, 62(10), 1284.
50. Yokogawa, K.; Ishizahi, J.; Ohkuma, S.; Myamoto, K. Influence of lipophilicity and lysosomal accumulation on tissue distribution kinetics of basic drugs: A physiologically based pharmacokinetic model. Methods Find. Exp. Clin. Pharmacol. 2002, 24 (2),81-93. (Pubitemid 34310988)
51. Boer, F. Drug handling by the lungs. Br. J. Anaesth., 2003, 91(1), 50-60. (Pubitemid 36857315)
52. Upton R.; Doolette, D. Kinetic aspects of drug disposition in the lungs. Clin. Exp. Pharmacol. Physiol. 1999, 26, 381-391. (Pubitemid 29306953)
53. Cooper, A.; Potter, T.; Luker, T. Prediction of efficacious inhalation lung doses via the use of in silico lung retention quantitative structure-activity relationship models and in vitro potency screens. Drug Metab. Disp., 2010, 38, 2218-2225.
54. Tunek, A.; Sjodin, K.; Hallstrom, G. Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug Metab. Disp., 1997, 25 (11), 1311-1317. (Pubitemid 27490677)
55. Tayab, Z., Fardon, T.; Lee, D.; Haggart, K.; MCFarlane, L.; Lipworth, B.; Hochhaus, G. Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. Br. J. Clin. Pharmacol., 2007, 64, 698-705. (Pubitemid 47568808)
56. Riley, R.; Martin, I.; Cooper, A. The influence of DMPK as an integrated partner in modern drug discovery. Current Drug Metabolism , 2002, 3(5), 527-50. (Pubitemid 34982181)
57. McGinnity, D.; Collington, J.; Austin, R.; Riley, R. Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Curr. Drug Met., 2007, 8(5), 463- 479. (Pubitemid 47603410)
58. Petzold, U.; Kremer, H.; Nguyen, D.; Munzel, U.; Dietrich, H.; Maus, J. Single-dose pharmacokinetics and safety pharmacodynamics of formoterol delivered by two different dry powder inhalers. J. Aerosol Med. Pulm. Drug Deliv., 2008, 21, 309-319.
59. Lähelmä, S.; Kirjavainen, M.; Kela, M.; Herttuainen, J.; Vahteristo, M.; Silvasti, M.; Ranki-Pesonen, M. Equivalent lung deposition of budesonide in vivo: A comparison of dry powder, inhalers using a pharmacokinetic method. J. Clin. Pharmacol., 2005, 59(2), 167- 173. (Pubitemid 40208852)
60. Du, X.; Zhu, Z.; Fu, Q.; Li, D.; Xu, W. Pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler in healthy volunteers. Acta Pharmacologica Sinica, 2002, 23(7), 663-666. (Pubitemid 34733333)
61. Davies, D. The fate of inhaled terbutaline. Eur. J. Respir. Dis., 1984, 134, 141-7. (Pubitemid 14138747)
62. Hvizdos, K.; Goa, K. Tiotropium bromide. Drugs, 2002, 62(8), 1195-1203. (Pubitemid 34587573)
63. Chaplin, M.; Cooper, W.; Segre, E.; Oren, J.; Jones, R.; Nerenberg, C. Correlation of flunisolide plasma levels to eosinopenic response in humans. J. Allergy Clin. Immunol., 1980, 65(6), 445-53. (Pubitemid 10125233)